PIMECROLIMUS , Amlitelimab, Matched placebo for test, Amlitelimab, -, TACROLIMUS clinical trials

A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis.

This study is testing a new medicine, amlitelimab, for moderate-to-severe eczema in people aged 12 and over. It compares amlitelimab to a dummy medicine (placebo) to see if it improves eczema symptoms like itching and skin clearing.